[go: up one dir, main page]

MX2022002881A - Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. - Google Patents

Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Info

Publication number
MX2022002881A
MX2022002881A MX2022002881A MX2022002881A MX2022002881A MX 2022002881 A MX2022002881 A MX 2022002881A MX 2022002881 A MX2022002881 A MX 2022002881A MX 2022002881 A MX2022002881 A MX 2022002881A MX 2022002881 A MX2022002881 A MX 2022002881A
Authority
MX
Mexico
Prior art keywords
methylmorpholino
chlorobenzyl
triazol
piperidin
amine
Prior art date
Application number
MX2022002881A
Other languages
English (en)
Inventor
Grzegorz Witkowski
Marta Magdycz
Magdalena Tyszkiewicz
Marcin Zakrzewski
Stanislaw Pikul
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of MX2022002881A publication Critical patent/MX2022002881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con un proceso para la síntesis de la 5-(4-((2S,5S)-5-(4-clorobencil)-2-metilmorfolino)pi peridin-1-il)-1H-1,2,4-triazol-3-amina en dos formas cristalinas hidratadas y en una forma cristalina anhidra. La presente invención además se relaciona con el (Z)-4-((2S,5S)-5-(4-clorobenc il)-2-metilmorfolino)-N-ciano-piperidina-1-carbimidotioato de metilo que es el compuesto intermediario en este proceso.
MX2022002881A 2019-09-25 2020-09-25 Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. MX2022002881A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905494P 2019-09-25 2019-09-25
PL43126919 2019-09-25
PCT/IB2020/058984 WO2021059220A1 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine

Publications (1)

Publication Number Publication Date
MX2022002881A true MX2022002881A (es) 2022-06-08

Family

ID=73139065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002881A MX2022002881A (es) 2019-09-25 2020-09-25 Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Country Status (14)

Country Link
US (2) US11746107B2 (es)
EP (1) EP4041726B8 (es)
JP (1) JP7697933B2 (es)
KR (1) KR20220069008A (es)
CN (1) CN114466845B (es)
AU (1) AU2020356534A1 (es)
BR (1) BR112022005420A2 (es)
CA (1) CA3155177A1 (es)
IL (1) IL291569B2 (es)
MX (1) MX2022002881A (es)
PH (1) PH12022550713A1 (es)
TW (3) TWI769532B (es)
WO (1) WO2021059220A1 (es)
ZA (1) ZA202204542B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
DE60126785T2 (de) * 2000-08-08 2007-10-25 Ortho-Mcneil Pharmaceutical, Inc. Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
BR112014026828A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche compostos de triazolo como inibidores de pde10
WO2015095701A1 (en) * 2013-12-20 2015-06-25 The Institute For Drug Delivery Substituted amino triazoles, and methods using same
US9440953B2 (en) 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
PL415078A1 (pl) * 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
CA3146715A1 (en) 2019-07-15 2021-01-21 Oncoarendi Therapeutics S.A. Substituted amino triazoles useful as chitinase inhibitors
MX2022002881A (es) 2019-09-25 2022-06-08 Oncoarendi Therapeutics Sa Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.

Also Published As

Publication number Publication date
JP7697933B2 (ja) 2025-06-24
TW202126644A (zh) 2021-07-16
IL291569B1 (en) 2024-12-01
TWI769532B (zh) 2022-07-01
US20240025889A1 (en) 2024-01-25
PH12022550713A1 (en) 2024-02-12
ZA202204542B (en) 2023-01-25
IL291569A (en) 2022-05-01
AU2020356534A1 (en) 2022-05-19
CN114466845B (zh) 2024-12-17
TWI892762B (zh) 2025-08-01
BR112022005420A2 (pt) 2022-06-21
TW202237594A (zh) 2022-10-01
EP4041726B8 (en) 2025-11-26
US11746107B2 (en) 2023-09-05
TWI849432B (zh) 2024-07-21
JP2022549863A (ja) 2022-11-29
IL291569B2 (en) 2025-04-01
EP4041726B1 (en) 2025-09-17
EP4041726C0 (en) 2025-09-17
KR20220069008A (ko) 2022-05-26
EP4041726A1 (en) 2022-08-17
US20210147401A1 (en) 2021-05-20
CN114466845A (zh) 2022-05-10
US12319677B2 (en) 2025-06-03
TW202448877A (zh) 2024-12-16
WO2021059220A1 (en) 2021-04-01
CA3155177A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
PE20091618A1 (es) 1,2,4-triazoles trisustituidos
ZA201906909B (en) Fungicidal oxadiazoles
AR074996A1 (es) Formas polimorficas de sal de clorhidrato de 3-(1-(3-(5-(1-metil-piperidin -4-ilmetoxi) -pirimidin-2-il)-bencil)-6-oxo-1,6-dihidro-piridazin-3-il)- benzonitrilo y sus procesos de preparacion
PE20170945A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
MX2022002881A (es) Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina.
RU2016133684A (ru) Бициклические азот-содержащие соединения как агонисты М1 мускариновых рецепторов
BR122015028990B8 (pt) composto, composições fungicidas e método de controle de doenças das plantas
PE20080545A1 (es) Isoxazolinas insecticidas
CY1111772T1 (el) Μονοϋδροχλωρικο μονοϋδρικο αλας 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλο)-5-τριφλουορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλο-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
MX2012001969A (es) Derivados de 3-[1-(3-haloalquil)-triazolil]-fenil-sulfuro como acaricidas e insecticidas.
ES2557478T3 (es) Compuestos de pirazol y triazol como inhibidores de KSP
CA2413243A1 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
CR20230162A (es) Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
WO2015019238A8 (en) Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
MX2009013808A (es) Nueva forma cristalina de 3-(difluorometil)-1-metil-n-(3',4',5'-tr ifluoro[1,1'-bifenil]-2-il)-1h-pirazol-4-carboxamida.
WO2008059551A3 (en) Process for the preparation of imatinib and intermediates thereof
BRPI0605907A2 (pt) processo aperfeiçoado para a preparação de letrozol
JP2005530753A5 (es)
CA2882821C (en) Pyrazole carboxamide derivatives and uses thereof as taar modulators
CO2022006098A2 (es) Derivados de 1 -(4-(4-(5-fenilo)-4,5-dihidroisoxazol-3-ilo)tiazol-2-ilo)piperidina-1-ilo) etano-1-ona y compuestos relacionados como fungicidas para la protección de cultivos
EA201071299A1 (ru) 5-[5-[2-(3,5-бис(трифторметил)фенил)-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил-2-алкилпролинамиды в качестве антагонистов рецептора nk1
CO2022007808A2 (es) Polimorfos del compuesto antifúngico de triazol pc945
CL2018003107A1 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo